amivantamab plus lazertinib is a new standard for egfr-mutant nsclc
Published 1 day ago • 342 plays • Length 3:50Download video MP4
Download video MP3
Similar videos
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
9:02
amivantamab plus lazertinib for egfr-mutant lung cancer following progression on osimertinib
-
2:32
management of aes from amivantamab and lazertinib for egfr-m nsclc
-
0:47
the future of amivantamab and lazertinib in egfr-mutant nsclc
-
6:15
mariposa: longer-term follow-up of amivantamab & lazertinib in egfr-m nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
2:04
mariposa-2: amivantamab chemo (± lazertinib) vs chemo in egfr-mutated nsclc post-osimertinib
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
2:07
papillon: amivantamab plus chemotherapy in nsclc with egfr exon 20 insertions
-
1:27
mariposa: follow-up of lazertinib with amivantamab or osimertinib in egfr-m nsclc
-
2:08
mariposa: mechanisms of resistance to 1l amivantamab lazertinib in pts with egfr-m nsclc
-
1:30
emerging treatment strategies in egfr-mutant nsclc: osimertinib combinations and beyond
-
1:05
metalmark: amivantamab and capmatinib in advanced nsclc
-
1:47
amivantamab and lazertinib in egfr met disease - 2022 program: targeted therapies forum - english